TOREFORANT

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H32N6
Molecular Weight	392.5404
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CCC(CCCNC2=NC=C(C3=NC4=C(C)C=C(C)C=C4N3)C(C)=N2)CC1

InChI

InChIKey=FCRFVPZAXGJLPW-UHFFFAOYSA-N

InChI=1S/C23H32N6/c1-15-12-16(2)21-20(13-15)27-22(28-21)19-14-25-23(26-17(19)3)24-9-5-6-18-7-10-29(4)11-8-18/h12-14,18H,5-11H2,1-4H3,(H,27,28)(H,24,25,26)

HIDE SMILES / InChI

Molecular Formula	C23H32N6
Molecular Weight	392.5404
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28233185 | https://www.ncbi.nlm.nih.gov/pubmed/30102965 | https://www.ncbi.nlm.nih.gov/pubmed/30124726 | https://www.ncbi.nlm.nih.gov/pubmed/27422891 | http://www.remedypublications.com/pharmacology-and-pharmaceutics/full-text/app-v2-id1013.php

Toreforant (JNJ-38518168) is an orally active, selective histamine H4 receptor antagonist. Toreforant was investigated as an agent for the treatment of active rheumatoid arthritis. While some improvement in rheumatoid arthritis signs/symptoms through week 12 was observed in the phase IIa study, no efficacy was observed with toreforant at lower doses in a subsequent phase IIb study. Toreforant has been tested in clinical studies in patients with asthma and psoriasis. Toreforant failed to provide therapeutic benefit in population of patients with uncontrolled, eosinophilic, persistent asthma. Toreforant efficacy at 30 and 60 mg was greater than placebo but did not meet predefined success criterion in patients with moderate-to-severe psoriasis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H4 receptor 20 Target ID: CHEMBL3759 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27422891 \| http://www.remedypublications.com/pharmacology-and-pharmaceutics/articles/pdfs_folder/app-v2-id1013.pdf	Antagonist 2778		8.4 nM [Ki]

PubMed

Title	Date	PubMed
Clinical Development of Histamine H(4) Receptor Antagonists.	2017	28233185
Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial.	2018 Aug 1	30124726
Toreforant, an orally active histamine H(4)-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study.	2019 Apr	30739130

Patents

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:11:25 UTC 2023` Edited by `admin` on `Sat Dec 16 09:11:25 UTC 2023`
Record UNII	U6LA7G393X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TOREFORANT

Official Name

English

TOREFORANT [USAN]

Common Name

English

JNJ-38518168

Code

English

Toreforant [WHO-DD]

Common Name

English

toreforant [INN]

Common Name

English

2-PYRIMIDINAMINE, 5-(5,7-DIMETHYL-1H-BENZIMIDAZOL-2-YL)-4-METHYL-N-(3-(1-METHYL-4-PIPERIDINYL)PROPYL)-

Systematic Name

English

5-(4,6-DIMETHYL-1H-BENZIMIDAZOL-2-YL)-4-METHYL-N-(3-(1-METHYL-4-PIPERIDINYL)PROPYL)-2-PYRIMIDINAMINE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29708